Nilotinib and Combination Chemotherapy in Treating Patients With Newly Diagnosed Acute Lymphoblastic Leukemia
Status:
Completed
Trial end date:
2014-07-01
Target enrollment:
Participant gender:
Summary
RATIONALE: Nilotinib may stop the growth of cancer cells by blocking some of the enzymes
needed for cell growth. Drugs used in chemotherapy work in different ways to stop the growth
of cancer cells, either by killing the cells or by stopping them from dividing. Giving
nilotinib together with combination chemotherapy may kill more cancer cells.
PURPOSE: This phase II trial is studying how well giving nilotinib together with combination
chemotherapy works in treating patients with newly diagnosed acute lymphoblastic leukemia.